QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications. Botanical Solution Inc. (BSI), innovator of sustainable, consistent and cost-effective Advanced Botanical Materials (ABM) for agricultural and pharmaceutical applications, has entered into a Partnership Agreement with Croda Pharma to build a robust, scalable and truly sustainable supply chain and deliver kilogram-quantities of QS-21 to the pharmaceutical industry. BSI and Croda Pharma are announcing this Partnership Agreement at the World Vaccine and Immunotherapy Congress West Coast 2022 in San Diego this week. QS-21 is a highly efficacious vaccine adjuvant. It is used
The post <strong>Botanical Solution Inc. (BSI) & Croda Pharma Partnership Agreement to Accelerate Production for GMP QS-21 </strong> appeared first on Pharma Mirror Magazine.
